Phosphatidylinositol (3,4,5)-trisphosphate (PIP3)

Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) is a critical phospholipid second messenger located in the inner leaflet of the plasma membrane. It is generated from phosphatidylinositol (4,5)-bisphosphate (PIP2) by the action of Class I phosphoinositide 3-kinases (PI3Ks) in response to extracellular stimuli such as growth factors and hormones. PIP3 serves as a docking site for proteins containing pleckstrin homology (PH) domains, most notably the serine/threonine kinase AKT and its activator PDK1, thereby initiating signaling cascades that regulate cell growth, survival, proliferation, and metabolism. The levels of PIP3 are tightly regulated by the phosphatase PTEN, which dephosphorylates it back to PIP2. Dysregulation of PIP3 levels, often through PI3K mutations or PTEN loss, is a hallmark of many human cancers and is also implicated in metabolic diseases like diabetes and inflammatory conditions. While many therapeutic strategies target the enzymes responsible for PIP3 metabolism, direct interference with PIP3-protein interactions using small molecule antagonists like PITenins or lipid analogs like perifosine represents an alternative approach to modulating this pathway.

Other names

PtdIns(3,4,5)P3Phosphatidylinositol 3,4,5-trisphosphate1-phosphatidyl-1D-myo-inositol 3,4,5-trisphosphatePtdInsP3

Drugs targeting this molecule primarily function by competitively binding to the pleckstrin homology (PH) domains of effector proteins or acting as lipid analogs, thereby preventing the recruitment and activation of signaling kinases like AKT and PDK1 at the plasma membrane.